Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 10/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.61 |
| ▸ | ALPL | P05186 | 2/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948421 | 1.00 | MCHR1 (0.61) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL3006664 | 0.94 | MCHR1 (0.66) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL3027665 | 0.89 | MCHR1 (0.61) | MCHR1ADRA2ANPY5RALPL | |
| SCHEMBL2197208 | 0.88 | MCHR1 (0.61) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL2197205 | 0.88 | MCHR1 (0.61) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL4736251 | 0.86 | MCHR1 (0.58) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL3947055 | 0.82 | MCHR1 (0.54) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL3947061 | 0.82 | MCHR1 (0.54) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| SCHEMBL4734475 | 0.81 | MCHR1 (0.54) | MCHR1ADRA2ANPY5RALPLHSD17B1 | |
| Hydrochloric Acid SCHEMBL6602860 | 0.81 | MCHR1 (0.53) | MCHR1ADRA2ANPY5RALPLHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | MCHR1 1/4885ADRA2A 131/4885NPY5R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.